Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 2/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | BUB1 | O43683 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15913256 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3NR1H2EPHX2 | |
| SCHEMBL3679572 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3NR1H2EPHX2 | |
| SCHEMBL15212714 | 0.91 | CHRM2 (0.39) | CHRM2CHRM1CHRM3NR1H2EPHX2 | |
| SCHEMBL15212838 | 0.91 | CHRM2 (0.39) | CHRM2CHRM1CHRM3NR1H2EPHX2 | |
| SCHEMBL20813371 | 0.91 | CHRM2 (0.39) | CHRM2CHRM1CHRM3NR1H2EPHX2 | |
| SCHEMBL27219245 | 0.91 | CHRM2 (0.39) | CHRM2CHRM1CHRM3NR1H2EPHX2 | |
| SCHEMBL3669650 | 0.91 | CHRM2 (0.39) | CHRM2CHRM1CHRM3NR1H2EPHX2 | |
| SCHEMBL19214900 | 0.91 | CHRM2 (0.39) | CHRM2CHRM1CHRM3NR1H2EPHX2 | |
| SCHEMBL23611102 | 0.88 | CHRM2 (0.34) | CHRM2CHRM1CHRM3 | |
| SCHEMBL5203966 | 0.88 | CHRM2 (0.41) | CHRM2CHRM1CHRM3NR1H2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1686996-A4 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-11-12 | — | — | EP | disclosed |
| US-7368453-B2 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1686996-A1 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | CHIRON CORPORATION (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1651229-A1 | GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS | Chiron Corporation (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050192297-A1 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION GLAXOSMITHKLINE | 2005-09-01 | — | — | US | disclosed |
| WO-2005051391-A1 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | CHIRON CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2004112793-A1 | GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192297-A1 | Quinazolinone compounds with reduced bioaccumulation | MC4R, MC2R, MC3R | CHRM2 79/4885CHRM1 51/4885CHRM3 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.